Analysis of techniques to obtain plasma for measurement of levels of free fatty acids.
Accuracy in measurement of plasma free fatty acids (FFA), and therefore prevention of the in vitro lipolysis, is a crucial step to understand the physiologic role of plasma FFA and their relationships in the pathogenesis of important metabolic disorders such as central obesity, insulin resistance, and diabetes mellitus. As lipoprotein triglyceride-fatty acids are elevated in these states, in vitro lipolysis of triglycerides may artifactually increase FFA. Plasma FFA were measured in subjects before and after heparin administration, under different experimental conditions affecting the in vitro activity of lipoprotein lipase (LPL) and hepatic lipase (HL). Paraoxon, a cholinesterase inhibitor neurotoxin known to block plasma lipolytic activity, and preextraction timing and temperature of collection were tested. Paraoxon was required to prevent triglyceride hydrolysis in: a) preheparin plasma allowed to stand at room temperature (21 degrees C) for 2 h, before being frozen at -20 degrees C (FFA = 1817 +/- 291 vs. 698 +/- 66 microEq/l, P < 0.005, mean +/- SEM, without and with paraoxon, respectively); and b) in postheparin plasma immediately stored at -20 degrees C (FFA = 2682 +/- 357 vs. 1299 +/- 150 microEq/l, P < 0.005, without and with paraoxon, respectively). No difference in the FFA level was found in preheparin plasma collected either with or without paraoxon when: a) the samples were placed in ice and immediately assayed; b) the specimens were immediately frozen at -70 degrees C and assayed 60 days later.(ABSTRACT TRUNCATED AT 250 WORDS)
Zambon
A
A
Department of Medicine, University of Washington, Seattle 98195.
Hashimoto
S I
SI
Brunzell
J D
JD
D016477:Artifacts; D001793:Blood Preservation / Q000379:methods; D001800:Blood Specimen Collection / Q000379:methods; D015925:Cryopreservation; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008049:Lipase / Q000097:blood / Q000187:drug effects; D008066:Lipolysis / Q000187:drug effects; D010261:Paraoxon / Q000494:pharmacology; D013048:Specimen Handling / Q000379:methods*
D005230:Fatty Acids, Nonesterified; D006493:Heparin; D008049:Lipase; D010261:Paraoxon